HUE035859T2 - Cladribine regimen for treating multiple sclerosis - Google Patents

Cladribine regimen for treating multiple sclerosis Download PDF

Info

Publication number: HUE035859T2
Authority: HU; Hungary
Prior art keywords: cladribine; months; period; administered; dose
Prior art date: 2004-12-22

Application number

HUE14001970A

Other languages

English (en)

Hungarian (hu)

Inventor

Luca Giampiero De

Arnaud Ythier

Alain Munafo

Maria Lopez-Bresnahan

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2005-12-20

Publication date

2018-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34930135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035859(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-20 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2018-05-28 Publication of HUE035859T2 publication Critical patent/HUE035859T2/en

Links

PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title claims description 322
229960002436 cladribine Drugs 0.000 title claims description 308
201000006417 multiple sclerosis Diseases 0.000 title claims description 65
230000006698 induction Effects 0.000 claims description 90
238000011282 treatment Methods 0.000 claims description 62
238000012423 maintenance Methods 0.000 claims description 53
108090000467 Interferon-beta Proteins 0.000 claims description 18
230000000750 progressive effect Effects 0.000 claims description 9
102000003996 Interferon-beta Human genes 0.000 claims description 8
229960001388 interferon-beta Drugs 0.000 claims description 7
208000034189 Sclerosis Diseases 0.000 claims description 6
206010030113 Oedema Diseases 0.000 claims 1
230000014759 maintenance of location Effects 0.000 claims 1
239000003826 tablet Substances 0.000 description 52
239000008194 pharmaceutical composition Substances 0.000 description 28
239000003921 oil Substances 0.000 description 22
235000019198 oils Nutrition 0.000 description 22
239000000203 mixture Substances 0.000 description 20
238000000034 method Methods 0.000 description 17
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 15
208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 15
201000010099 disease Diseases 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
238000009472 formulation Methods 0.000 description 13
238000002595 magnetic resonance imaging Methods 0.000 description 13
239000003814 drug Substances 0.000 description 11
102100026720 Interferon beta Human genes 0.000 description 10
108010005716 Interferon beta-1a Proteins 0.000 description 9
102000014150 Interferons Human genes 0.000 description 9
108010050904 Interferons Proteins 0.000 description 9
230000002045 lasting effect Effects 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
238000011419 induction treatment Methods 0.000 description 7
229940079322 interferon Drugs 0.000 description 7
230000003902 lesion Effects 0.000 description 7
201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 7
229920000858 Cyclodextrin Polymers 0.000 description 6
230000002411 adverse Effects 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000011418 maintenance treatment Methods 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
206010051290 Central nervous system lesion Diseases 0.000 description 5
-1 chlorinated purine analogue 2-chloro-2’deoxyadenosine analogue Chemical class 0.000 description 5
229940038850 rebif Drugs 0.000 description 5
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
239000002775 capsule Substances 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000005713 exacerbation Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
206010063401 primary progressive multiple sclerosis Diseases 0.000 description 4
238000011084 recovery Methods 0.000 description 4
208000016192 Demyelinating disease Diseases 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
108010005714 Interferon beta-1b Proteins 0.000 description 3
240000007594 Oryza sativa Species 0.000 description 3
235000007164 Oryza sativa Nutrition 0.000 description 3
206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
229940003504 avonex Drugs 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
235000009566 rice Nutrition 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000028698 Cognitive impairment Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010012305 Demyelination Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010060860 Neurological symptom Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229940021459 betaseron Drugs 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229960004461 interferon beta-1a Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000012332 laboratory investigation Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
208000024806 Brain atrophy Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
108010072051 Glatiramer Acetate Proteins 0.000 description 1
206010018341 Gliosis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
238000012307 MRI technique Methods 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229940037003 alum Drugs 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007374 clinical diagnostic method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
231100000870 cognitive problem Toxicity 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
229940038717 copaxone Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000007387 gliosis Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000036737 immune function Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000002483 medication Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Chemical And Physical Treatments For Wood And The Like (AREA)
Pressure Welding/Diffusion-Bonding (AREA)

HUE14001970A 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis HUE035859T2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63866904P	2004-12-22	2004-12-22
EP04106909		2004-12-22

Publications (1)

Publication Number	Publication Date
HUE035859T2 true HUE035859T2 (en)	2018-05-28

Family

ID=34930135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE14001970A HUE035859T2 (en)	2004-12-22	2005-12-20	Cladribine regimen for treating multiple sclerosis

Country Status (11)

Country	Link
AT (1)	ATE547106T1 (uk)
CY (1)	CY1125491T1 (uk)
DK (1)	DK1827461T3 (uk)
ES (4)	ES2428741T3 (uk)
HU (1)	HUE035859T2 (uk)
LT (1)	LT2805723T (uk)
ME (1)	ME01333B (uk)
PT (4)	PT3332789T (uk)
RS (1)	RS52219B (uk)
SI (1)	SI1827461T1 (uk)
UA (1)	UA96260C2 (uk)

2005
- 2005-12-20 LT LTEP14001970.4T patent/LT2805723T/lt unknown
- 2005-12-20 ES ES10182632T patent/ES2428741T3/es not_active Expired - Lifetime
- 2005-12-20 AT AT05823474T patent/ATE547106T1/de active
- 2005-12-20 ME MEP-2012-35A patent/ME01333B/me unknown
- 2005-12-20 UA UAA200708371A patent/UA96260C2/uk unknown
- 2005-12-20 PT PT181516345T patent/PT3332789T/pt unknown
- 2005-12-20 RS RS20120161A patent/RS52219B/sr unknown
- 2005-12-20 DK DK05823474.1T patent/DK1827461T3/da active
- 2005-12-20 SI SI200531514T patent/SI1827461T1/sl unknown
- 2005-12-20 ES ES14001970.4T patent/ES2666146T3/es not_active Expired - Lifetime
- 2005-12-20 PT PT05823474T patent/PT1827461E/pt unknown
- 2005-12-20 ES ES10182676.6T patent/ES2495392T3/es not_active Expired - Lifetime
- 2005-12-20 ES ES05823474T patent/ES2382554T3/es not_active Expired - Lifetime
- 2005-12-20 HU HUE14001970A patent/HUE035859T2/en unknown
- 2005-12-20 PT PT221666100T patent/PT4070800T/pt unknown
- 2005-12-20 PT PT140019704T patent/PT2805723T/pt unknown
2022
- 2022-06-21 CY CY20221100424T patent/CY1125491T1/el unknown

Also Published As

Publication number	Publication date
PT2805723T (pt)	2018-01-25
CY1125491T1 (el)	2025-05-09
ME01333B (me)	2013-12-20
SI1827461T1 (sl)	2012-05-31
LT2805723T (lt)	2018-02-12
PT1827461E (pt)	2012-05-07
UA96260C2 (uk)	2011-10-25
PT3332789T (pt)	2022-07-05
PT4070800T (pt)	2024-12-30
ES2495392T3 (es)	2014-09-17
ES2666146T3 (es)	2018-05-03
RS52219B (sr)	2012-10-31
ES2382554T3 (es)	2012-06-11
ATE547106T1 (de)	2012-03-15
ES2428741T3 (es)	2013-11-11
DK1827461T3 (da)	2012-03-26

Publication	Publication Date	Title
US8377903B2 (en)	2013-02-19	Cladribine regimen for treating multiple sclerosis
HK40083827A (en)	2023-07-07	Cladribine regimen for treating multiple sclerosis
HUE035859T2 (en)	2018-05-28	Cladribine regimen for treating multiple sclerosis
HK40083827B (en)	2025-03-21	Cladribine regimen for treating multiple sclerosis
CN101090726A (zh)	2007-12-19	治疗多发性硬化的克拉屈滨方案
HK1110517A (en)	2008-07-18	Cladribine regimen for treating multiple sclerosis